Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Strategy & Product Portfolio
BMY logo

Bristol Myers Squibb's 2023 Revenue Down 2% to $45.0B Amidst Revlimid Generic Erosion, New Products Up 77%

BMY10-KFiling Date: 2/13/2024
Bristol Myers Squibb Company
Description

What this story covers

Bristol Myers Squibb's 2023 revenue decreased 2 percent to 45 point 0 billion dollars due to Revlimid generic erosion, offset by new product growth (up 77 percent). They face intense pricing, regulatory, and IP challenges, while investing heavily in R and D and strategic acquisitions.

Story snapshot

CompanyBristol Myers Squibb Company
TickerBMY
VariantStandard detailed
Duration25:50
Filing type10-K
PeriodAnnual 2023
IndustryHealthcare & Pharmaceuticals
Accession0000014272-24-000044

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in